Table 1. Patients' characteristics in the TS and VS (overall population, N=1104).
| TS N (%) | VS N (%) | P-value | |
|---|---|---|---|
| Number of patients | 596 (100) | 508 (100) | – |
|
Gender | |||
| Male | 359 (60.2) | 318 (62.6) | 0.46 |
| Female | 237 (39.8) | 190 (37.4) | |
|
Age (years) | |||
| <65 | 287 (48.2) | 224 (44.1) | 0.20 |
| ⩾65 | 309 (51.8) | 284 (55.9) | |
|
ECOG-PS | |||
| 0–1 | 468 (78.5) | 433 (85.2) | <0.0001 |
| ⩾2 | 10 (1.7) | 75 (14.8) | |
| Missing | 118 (19.8) | 0 (0) | |
|
Driver mutation | |||
| Wt | 227 (38.1) | 213 (41.8) | 0.96 |
| BRAF mutant (V600E) | 54 (9.1) | 49 (9.6) | |
| RAS mutant | 315 (52.8) | 246 (48.6) | |
|
Number of metastatic sites | |||
| 1 | 378 (63.4) | 216 (42.5) | <0.0001 |
| >1 | 218 (36.6) | 292 (57.5) | |
|
Peritoneal metastases | |||
| Yes | 130 (21.8) | 107 (21.1) | 0.82 |
| No | 466 (78.2) | 401 (78.9) | |
|
Lung metastases | |||
| Yes | 147 (24.7) | 152 (29.9) | 0.06 |
| No | 449 (75.3) | 356 (70.1) | |
|
Synchronous metastases | |||
| Yes | 412 (69.1) | 367 (72.2) | 0.29 |
| No | 184 (30.9) | 141 (27.8) | |
|
Distant lymph-node metastases | |||
| Yes | 117 (19.6) | 110 (21.7) | 0.45 |
| No | 479 (80.4) | 398 (78.3) | |
|
Mucinous histology | |||
| Yes | 110 (18.5) | 76 (15.0) | <0.0001 |
| No | 395 (66.3) | 416 (81.9) | |
| Missing | 91 (15.3) | 16 (3.1) | |
|
Primary tumour site | |||
| Right | 202 (33.9) | 162 (31.9) | 0.52 |
| Left | 394 (66.1) | 346 (68.1) | |
|
Primary tumour resected | |||
| Yes | 466 (78.2) | 344 (67.8) | <0.0001 |
| No | 130 (21.8) | 164 (32.2) | |
|
Tumour grading | |||
| G1–2 | 248 (41.6) | 143 (28.1) | <0.0001 |
| G3–4 | 195 (32.7) | 221 (43.5) | |
| Missing | 153 (25.7) | 144 (28.3) | |
Abbreviations: N=number; PS=performance status; TS=training set; VS=validation set; wt=wild type.
%: rate; P-value: χ2 test.